Financials in USD. Standardized financial statements.
A compact view of how PD-Rx Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $18.35M | $18.95M | $21.27M | $28.72M | $21.60M | $21.03M | $20.87M | $24.97M | $25.99M | $21.47M |
| Revenue Growth? | -3.2% | -10.9% | -25.9% | +32.9% | +2.7% | +0.7% | -16.4% | -3.9% | +21.1% | 0.0% |
| Cost of Revenue? | $0 | $13.32M | $14.56M | $17.65M | $14.65M | $14.77M | $13.29M | $16.43M | $18.15M | $13.90M |
| Gross Profit? | $0 | $5.62M | $6.71M | $11.06M | $6.96M | $6.26M | $7.58M | $8.54M | $7.84M | $7.57M |
| Gross Margin? | 0.0% | +29.7% | +31.6% | +38.5% | +32.2% | +29.8% | +36.3% | +34.2% | +30.2% | +35.3% |
| Operating Expenses? | $0 | $6.58M | $6.90M | $7.03M | $6.08M | $6.50M | $7.65M | $7.64M | $6.86M | $6.80M |
| Operating Income? | -$477,417 | -$952,018 | -$190,477 | $4.00M | $876,470 | -$237,650 | -$65,730 | $890,720 | $973,840 | $763,170 |
| EBITDA? | -$477,417 | -$560,022 | $12,281 | $4.13M | $1.95M | -$39,509 | $162,892 | $1.16M | $1.18M | $970,304 |
| Income Before Tax | $0 | -$712,301 | -$126,776 | $4.05M | $1.83M | -$200,534 | -$14,435 | $980,801 | $1.03M | $798,297 |
| Income Tax Expense | $0 | $41,194 | -$28,712 | $1.02M | -$21,632 | $183,607 | -$1,516 | $359,638 | $403,485 | $290,625 |
| Net Income? | -$257,523 | -$753,495 | -$98,064 | $3.03M | $1.86M | -$384,141 | -$12,919 | $621,163 | $626,966 | $507,672 |
| EPS? | $-0.17 | $-0.46 | $-0.06 | $1.83 | $1.08 | $-0.22 | $-0.01 | $0.36 | $0.36 | $0.30 |
| Diluted EPS? | $-0.17 | $-0.46 | $-0.06 | $1.83 | $1.08 | $-0.22 | $-0.01 | $0.36 | $0.36 | $0.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality